SomaLogic news and events

For all news and media-related matters, please contact

Recent news

A study published online today in the Journal of the American Medical Association (JAMA) details the first successful effort to measure at scale the levels of more than a thousand proteins in blood in patients with coronary heart disease (CHD), and describes the identification of a combination of nine specific proteins whose levels taken together can accurately predict the risk of future heart attacks, strokes, heart failure or death. This 9-protein model is more accurate for predicting risk of such adverse events than any currently measured risk factors (e.g., cholesterol, blood pressure, diabetes, smoking or age). A diagnostic test based on these findings is in development for release later this year.

SomaLogic announced today that it has signed an agreement with University College London (UCL) to deploy SomaLogic’s proprietary SOMAscan assay in the UCL Genomics laboratory. This agreement marks the first placement of the assay in the University of London large network of self-governing colleges and research institutes.

SomaLogic, Inc., and Visium Healthcare Partners, LP today announced that SomaLogic will receive up to $60.5 million through a combination of debt and equity financing from Visium. The proceeds will be used to support SomaLogic’s continued growth, including its primary focus on the development of novel life science tools and clinical diagnostics based on the Company’s proprietary proteomics technology. Specific terms of the agreement were not disclosed.

For archived news and press releases, visit our archive.